-
Global Biotechnology & Pharmaceutical Markets1 month ago9 pharma leaders sound ‘alarm bells’ on biotech’s decline in Europe
Frustrated by a slump that’s seen Europe lose ground to the U.S. and China, several top drugmakers are calling for speedier clinical trials, intellectual property protections...
-
Global Biotechnology & Pharmaceutical Markets1 month agoSTAT+: Pharmalittle: We’re reading about a closing loophole for importing meds, European competitiveness, and more
As of next month, a loophole that allows Americans to personally import their medications by mail is closing
-
Global Biotechnology & Pharmaceutical Markets1 month ago15 biotech companies in China you should know about
Check out 10 of the top biotech companies in China, as the country has seen its biotech sector grow in the last decade. The post 15...
-
Global Biotechnology & Pharmaceutical Markets1 month agoDiabetes Drug Face-Off: New Japanese Trial Tests Whether a Popular SGLT2 Inhibitor Eats Away at Muscle
A large share of Japanese patients living with type 2 diabetes are older adults who are not obese, a population that has been largely invisible in...
-
Global Biotechnology & Pharmaceutical Markets1 month ago
GSK aiming to ‘balance West and East’ after Hansoh deal success showed China’s potential
GSK has been operating a strategy of “balancing the West and the East” since the Big Pharma’s eyes were opened to the potential of licensing drugs...
-
Global Biotechnology & Pharmaceutical Markets1 month agoSTAT+: Pharmalittle: We’re reading about pharma seeking to protect China deals, a Roche obesity drug, and more
Western pharmaceutical companies are urging the Trump administration to allow them to keep doing deals with Chinese companies for drug candidates
-
Global Biotechnology & Pharmaceutical Markets1 month agoUK needs ‘clearer path for dementia diagnosis and treatment’
UK Prime Minister Andy Burnham, who lost his father to Alzheimer's last week, has been urged to implement a "cancer-style" reform of dementia care.
-
Global Biotechnology & Pharmaceutical Markets1 month ago
‘Europe does not value what you do’: 9 pharmas make urgent call for bloc to beef up innovation muscle
As China and the U.S. presently duke it out over biopharma innovation supremacy, a clutch of Europe’s biggest drugmakers are calling on the bloc to not...
-
Global Biotechnology & Pharmaceutical Markets1 month agoA hidden tradeoff in Trump’s drug pricing deals
The government has announced “most-favored-nation” pricing agreements with 26 pharma companies. But the deals could stymie other plans to lower the country’s spending on prescription drugs.
-
Global Biotechnology & Pharmaceutical Markets1 month agoUK first country to launch CSL’s trivalent flu shot Aujemflu
CSL Seqirus' recently approved trivalent, cell-based influenza vaccine Aujemflu will be part of the UK's 2027/28 immunisation campaign.
Genmab’s cancer bispecific delivers early survival win in ‘exceedingly positive’ Phase 3 readout
Genmab’s cancer bispecific delivers early OS win in ‘exceedingly positive’ Phase 3 readout
STAT+: HHS moves to allow compounding of some unapproved peptides
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
